Lobbying Filing Details

Total Spending

$920,000

Activities

3

Lobbyists

5

Gov't Entities

6

Filing Information
Filing UUID:
1d459d29-e267-42ee-a108-a7c99f2bc79c
Type:
Q4 - 4th Quarter - Report
Period:
2023 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 18, 2024 at 4:31 PM
Income:
$0
Expenses:
$920,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Samantha Ventimiglia
Registrant
VERTEX PHARMACEUTICALS INCORPORATED

Global biotechnology company

Boston, Massachusetts
Client
VERTEX PHARMACEUTICALS INCORPORATED
Massachusetts, United States of America
Lobbying Activities (3)
Activity 1
Health Issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.

Lobbyists (5)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • ERIN MENDELSOHN
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Medicare/Medicaid

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.

Lobbyists (5)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • ERIN MENDELSOHN
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Taxation/Internal Revenue Code

Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)

Lobbyists (2)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.